Atwater Malick’s Bristol-Myers Squibb BMY Stock Holding History

Atwater Malick’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-125	Closed	-$6K	–	61
2019 Q3	$6K	Buy	+125	New	+$5.88K	0.01%	161

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Atwater Malick's BMY Position: Q4 2019 in Review

Atwater Malick sold out of Bristol-Myers Squibb (BMY) in Q4 2019, closing a stake of 125 shares — an estimated $6K sold.

Atwater Malick first reported a position in BMY in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 2,218 funds tracked by Wall St. Rank hold BMY as of Q4 2019.

Atwater Malick reported no remaining Bristol-Myers Squibb position as of Q4 2019 after selling out during the quarter.
Atwater Malick sold 125 Bristol-Myers Squibb shares in Q4 2019, an estimated $6K.
Atwater Malick first reported a position in Bristol-Myers Squibb in Q3 2019 and held it in 1 quarter.
Atwater Malick's Bristol-Myers Squibb position peaked at $6K in Q3 2019.
2,218 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2019.

Based on Atwater Malick's 13F filing for Q4 2019, filed 7 Jan 2020.